Yiming Kaier Biopharmaceutical Technology

Yiming Kaier Biopharmaceutical Technology is a Chinese biotechnology company focused on the development of innovative cancer immunotherapies. The company specializes in the discovery and engineering of next-generation biologics, including high-affinity monoclonal antibodies and bispecific antibodies targeting solid tumors and hematological malignancies. Their research primarily centers on high-value targets such as Claudin 18.2 and GPRC5D, utilizing advanced cell therapy and antibody engineering platforms. Yiming Kaier aims to address unmet medical needs in oncology through the development of precision medicines with enhanced efficacy and safety profiles.